NASDAQ · Healthcare
Invest in Immutep stock from India
Indian and foreign residents can buy Immutep (IMMP) shares directly through Paasa.
By Paasa · Updated
Immutep at a glance
- Price
- $0.26+$0.00 (0.57%)
- Market cap
- $38.83M
- Day range
- $0.26 – $0.28
- P/E
- -0.67
- Dividend yield
- None
- Volume
- 648.29K
- 1 month
- -30.66%
- 6 months
- -26.83%
- YTD
- -90.79%
- 1 year
- -84.68%
- 5 years
- -93.48%
Immutep statements, FY2022–FY2026
| Fiscal year | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | A$14.2M | A$5.0M | A$3.8M | A$3.5M | A$170.4K |
| Gross profit | A$11.8M | −A$56.4M | −A$37.7M | A$1.4M | −A$1.9M |
| Operating income | −A$82.0M | −A$126.4M | −A$88.1M | −A$77.7M | −A$33.9M |
| Net income | −A$77.6M | −A$61.4M | −A$42.7M | −A$39.9M | −A$32.2M |
| Earnings per share | −A$0.53 | −A$0.42 | −A$0.36 | −A$0.44 | −A$0.37 |
| EBITDA | −A$79.6M | −A$62.9M | −A$44.5M | −A$39.6M | −A$31.9M |
| Total assets | A$83.3M | A$157.0M | A$201.6M | A$147.4M | A$102.2M |
| Total debt | A$1.0M | A$1.6M | A$1.6M | A$1.2M | A$1.7M |
| Cash and short-term investments | A$68.9M | A$129.7M | A$181.9M | A$123.4M | A$80.0M |
| Shareholders' equity | A$61.5M | A$143.6M | A$189.5M | A$136.5M | A$94.1M |
| Operating cash flow | −A$54.3M | −A$62.0M | −A$34.8M | −A$35.9M | −A$30.2M |
| Free cash flow | −A$54.3M | −A$62.1M | −A$35.8M | −A$35.9M | −A$30.3M |
| Capital expenditure | −A$90.9K | −A$45.8K | −A$932.4K | −A$47.0K | −A$22.9K |
Fiscal years as reported, the latest ending 30 Jun 2026. Figures in AUD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Candel Therapeutics | CADL | $11.02 | $807.44M |
| Achieve Life Sciences | ACHV | $7.54 | $774.05M |
| Allogene Therapeutics | ALLO | $1.65 | $569.51M |
| Capricor Therapeutics | CAPR | $8.36 | $480.79M |
| Editas Medicine | EDIT | $2.58 | $395.93M |
| Cabaletta Bio | CABA | $2.07 | $337.52M |
| Vanda Pharmaceuticals | VNDA | $5.05 | $303.68M |
| Entrada Therapeutics | TRDA | $6.16 | $239.13M |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- $3.50
- High
- $5.00
- Median
- $4.25
- Consensus
- $4.25
Ratings: 2 buy · 2 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in USD, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in Immutep from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit.
Step 3
Search IMMP and buy
Find Immutep by name or by its ticker, IMMP, and place your order. Fractional shares are available and there is no minimum trade size, so you can buy by amount instead of whole shares.
Why invest in Immutep from India
What Immutep does
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. Immutep operates in the Biotechnology industry within the Healthcare sector.
Hold a dollar asset
Immutep shares are priced in US dollars, so a weaker rupee adds to what they're worth in rupees. The rupee depreciated over 85% against the dollar between 2010 and 2025.
Buy a fraction of a share
Buy by amount, not by share, and get the matching fraction of one Immutep share. There is no minimum trade size.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Immutep stock from India?
Yes. Indian residents and NRIs can buy Immutep (IMMP) shares directly through Paasa. Immutep is listed on NASDAQ, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
Do I need to buy a full Immutep share?
No. You can buy part of one Immutep share and add to your position over time. One share is $0.26, and you can buy whole shares or any fraction; there is no minimum trade size.
How are Immutep dividends taxed for Indian investors?
Immutep trades on NASDAQ but is domiciled in Australia, so any withholding on its dividends follows that country's rules rather than those of the US. What trades there is a depositary receipt over Immutep shares rather than the ordinary share itself. Some non-US companies list in the US through American Depositary Receipts, which can carry dividend withholding at the company's home-country rate. Dividends are taxed at your slab rate in India. Paasa's dividend report shows the gross amount and any tax withheld for each payment.
What tax do I pay in India when I sell Immutep shares?
The US does not levy capital gains tax on shares for Indian residents. In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the USD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.